In clinical research, PYR has demonstrated effective improvements in disease‐free and overall survival in patients with HER2‐positive breast cancer.[10] Nonetheless, the free form of this small‐molecule chemotherapeutic agent has limitations such as poor bioavailability and short action period, and is associated with systemic and organ toxicity. This evidence concerns the gene ERBB2 and breast cancer.